Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.

Jan 9, 2025 · Intellia is building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.

Learn more about Intellia, a clinical-stage genome editing company, developing novel, potentially curative therapeutics using CRISPR.

Jan 9, 2025 · CAMBRIDGE, Mass , Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on …

Jan 6, 2025 · The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.

Today, scientists at Intellia are developing this technology to make targeted changes to genes directly implicated in human disease. In the future, Intellia hopes to use its CRISPR technology …

Intellia is committed to developing gene editing treatments for those living with severe and life-threatening genetic diseases. We are currently investigating our CRISPR-based technology in …

Intellia is engineering T cells against specific cancer antigens. therapies to provide them with particular enhanced attributes that may more effectively treat oncological and autoimmune …

Find the latest Scientific Publications & Presentations from Intellia, a clinical-stage genome editing company.

At Intellia, we are revolutionizing medicine by harnessing the power of genome editing to develop CRISPR one-time treatments. We bring new hope for people living with conditions, including …